biib061
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2013 (NCT02071121)
Timeline
Indications
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
MAPT inhibitor
May lead to replacement of myelin on damaged nerve fibres
- Unspecified targetOTHER
Unknown
May lead to replacement of myelin on damaged nerve fibres
- Unspecified targetUnknown
Unknown
May lead to replacement of myelin on damaged nerve fibres
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833331 ↗
Also known as
- biib061
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04079088 | Phase 2 | Dec 19, 2019 | Biogen |
| NCT02521545 | Phase 1 | Jul 1, 2015 | Biogen |
| NCT02228707 | Phase 1 | Aug 1, 2014 | Biogen |
| NCT02071121 | Phase 1 | Dec 1, 2013 | Biogen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 4 | 4 | 2 | 2013 |
1 organizations
Page 1 / 1